2014
DOI: 10.47895/amp.v48i3.1126
|View full text |Cite
|
Sign up to set email alerts
|

Socio-cognitive Factors and Perceived Barriers: Their Influence on the Patient’s Adherence to Pulmonary Tuberculosis Treatment

Abstract: ...

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…27 The overall pooled estimated prevalence for the Asia region was 17% (95% CI 16% to 18%). The highest pooled prevalence was noted in Southern Asia (22% (95% CI 16% to 29%)), [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42] followed by Eastern Asia (18% (95% CI 16% to 20%)), [43][44][45][46][47][48][49][50][51][52][53][54][55] South East Asia (16% (95% 4% to 28%)), [56][57][58][59][60][61] Western Asia (10% (95% 5% to 15%)) [62][63][64] and Central Asia (6% (95% CI 5% to 7%)). 65 66 (figure 2) Subgroup analysis based on the duration of treatment interruption (36 studies, excluded non-defined duration of treatment interruption), demonstrated the pooled prevalence for ≥2 months interruption was 10% (95% CI 9% to 11%), which was much lower than another subgroup that considered the minimum duration of <2 months, 28% (95% CI 20% to 36%) (online supplemental figure S1).…”
Section: Prevalence Of Tb Treatment Interruptionmentioning
confidence: 99%
“…27 The overall pooled estimated prevalence for the Asia region was 17% (95% CI 16% to 18%). The highest pooled prevalence was noted in Southern Asia (22% (95% CI 16% to 29%)), [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42] followed by Eastern Asia (18% (95% CI 16% to 20%)), [43][44][45][46][47][48][49][50][51][52][53][54][55] South East Asia (16% (95% 4% to 28%)), [56][57][58][59][60][61] Western Asia (10% (95% 5% to 15%)) [62][63][64] and Central Asia (6% (95% CI 5% to 7%)). 65 66 (figure 2) Subgroup analysis based on the duration of treatment interruption (36 studies, excluded non-defined duration of treatment interruption), demonstrated the pooled prevalence for ≥2 months interruption was 10% (95% CI 9% to 11%), which was much lower than another subgroup that considered the minimum duration of <2 months, 28% (95% CI 20% to 36%) (online supplemental figure S1).…”
Section: Prevalence Of Tb Treatment Interruptionmentioning
confidence: 99%